The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces a milestone in the Foundation's impact on the Parkinson's disease (PD) therapeutic landscape.
Sunovion Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its Kynmobi (apomorphine hydrochloride) sublingual film (APL-130277) to treat Parkinson’s disease (PD) off episodes.